Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

Published:2018-08 Issue:4 Volume:16 Page:e777-e784
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Angelergues Antoine,Efstathiou Eleni,Gyftaki Revekka,Wysocki Piotr Jan,Lainez Nuria,Gonzalez Iria,Castellano Daniel E.,Ozguroglu Mustafa,Carbonero Iciar Garcia,Flechon Aude,Borrega Pablo,Guillot Aline,Balea Begona Campos,Le Moulec Sylvestre,Esteban Emilio,Munarriz Javier,Rubio Gustavo,Birtle Alison J.,Delanoy Nicolas,Bellmunt Joaquim,Oudard Stéphane

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference31 articles.

1. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer;Cornford;Eur Urol,2017

2. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA;Oudard;J Clin Oncol,2017

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

4. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer;van Soest;Eur J Cancer,2015

5. Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence;Jones;Eur Urol,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer;Reports of Practical Oncology and Radiotherapy;2024-01-23

2. Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy;Clinical Genitourinary Cancer;2023-06

3. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?;Expert Review of Pharmacoeconomics & Outcomes Research;2022-12-28

4. Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound;European Journal of Nuclear Medicine and Molecular Imaging;2022-11-08

5. Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer;Translational Cancer Research;2022-08